Frankfurt - Delayed Quote EUR
Cidara Therapeutics, Inc. (20D0.F)
As of 3:43 PM GMT+1. Market Open.
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
53,870.00
63,905.00
64,448.00
49,572.00
12,067.00
Cost of Revenue
--
1,523.00
--
--
--
Gross Profit
--
62,382.00
64,448.00
--
--
Operating Expense
82,582.00
86,865.00
97,951.00
91,827.00
83,916.00
Operating Income
-30,235.00
-24,483.00
-33,503.00
-42,255.00
-71,849.00
Net Non Operating Interest Income Expense
3,279.00
1,995.00
191.00
-212.00
-262.00
Pretax Income
-111,839.00
-22,488.00
-33,312.00
-42,467.00
-72,111.00
Tax Provision
403.00
443.00
272.00
--
--
Net Income Common Stockholders
-113,855.00
-22,931.00
-33,584.00
-42,467.00
-74,873.00
Diluted NI Available to Com Stockholders
-113,855.00
-22,931.00
-33,584.00
-42,467.00
-74,873.00
Basic EPS
-25.00
-5.20
-8.60
-16.20
-36.00
Diluted EPS
-25.00
-5.20
-8.60
-16.20
-36.00
Basic Average Shares
4,536.50
4,371.37
3,492.88
2,622.67
2,077.87
Diluted Average Shares
4,536.50
4,371.37
3,492.88
2,622.67
2,077.87
Total Operating Income as Reported
-115,118.00
-24,483.00
-33,503.00
-42,255.00
-71,849.00
Total Expenses
84,105.00
88,388.00
97,951.00
91,827.00
83,916.00
Net Income from Continuing & Discontinued Operation
-113,855.00
-22,931.00
-33,584.00
-42,467.00
-72,111.00
Normalized Income
-45,184.43
-22,931.00
-33,584.00
-42,467.00
-72,111.00
Interest Income
--
1,995.00
191.00
--
--
Net Interest Income
3,279.00
1,995.00
191.00
-212.00
-262.00
EBIT
-30,235.00
-24,483.00
-33,503.00
-42,255.00
-71,849.00
EBITDA
-30,061.00
-24,365.00
-33,360.00
-42,255.00
-70,799.00
Reconciled Cost of Revenue
--
1,523.00
--
--
--
Reconciled Depreciation
174.00
118.00
143.00
-1,230.00
1,050.00
Net Income from Continuing Operation Net Minority Interest
-112,242.00
-22,931.00
-33,584.00
-42,467.00
-72,111.00
Total Unusual Items Excluding Goodwill
-84,883.00
--
--
--
--
Total Unusual Items
-84,883.00
--
--
--
--
Normalized EBITDA
54,822.00
-24,365.00
-33,360.00
-42,255.00
-70,799.00
Tax Rate for Calcs
0.00
0.00
0.00
--
--
Tax Effect of Unusual Items
-17,825.43
--
--
--
--
12/31/2020 - 4/27/2015
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
Upgrade